New drug policy angers multinationals

Multinational drug manufacturers complained that their newly-invented and original drugs, which have already been undervalued in Korea, have been dealt a serious blow by the Korean government's plan to allow only cost-effective drugs to be covered by national health insurance.

They argued that under the so-called positive list plan, multinational pharmaceuticals are restricted from bringing ...